InSysBio to participate in ASCPT 2020

events
Conference
February 19, 2020

February 19, 2020

InSysBio announced its participation in 121st Annual meeting of American Society for Clinical Pharmacology and Therapeutics (ASCPT 2020) which is to be held on March 18-21, 2020 at Marriott Marquis Houston, TX.
InSysBio welcomes visitors at the booth # 102. Oleg Demin, CEO of InSysBio, Tatiana Karelina, lead modeler in Alzheimer’s Disease and Veronika Musatova, Head of IRT development team, will present the new version of IRT (Immune Response Template) and Cytocon DB (Cell and cYTOkine CONcentrations).
Additionally InSysBio team will present three posters at the Conference. Two of them will also be presented in frames of Poster Walk I, which provides an opportunity to discuss intriguing posters and the latest discoveries in the field:

Wednesday, March 18:

(Poster Walk I - Quantitative Systems Pharmacology)

  • PWI-001 “Development an approach to mechanistic modeling of CD4 T cell polarization” by Oleg Demin
  • PWI-003 “Quantitative systems pharmacology model of Alzheimer’s disease predicts effect of tau directed immunotherapy on multiple biomarkers” by Tatiana Karelina

Friday, March 20:

(Poster Session III)

  • PIII-124 “Development an approach to mechanistic modeling of CD4 T cell polarization” by Oleg Demin
  • PIII-126 “In Vitro to In Vivo Translation of EC50 of Mediators Released by Cells Forming Cell-to-Cell Contact” by Veronika Musatova
  • PIII-132 “Quantitative systems pharmacology model of Alzheimer’s disease predicts effect of tau directed immunotherapy on multiple biomarkers” by Tatiana Karelina

About InSysBio

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.